The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10B | Blood glucose lowering drugs, excl. insulins | |
4
|
A10BB | Sulfonamides, urea derivatives | |
5
|
A10BB07 | Glipizide |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 10 mg |
| Active Ingredient |
|---|
|
Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue. |
| Document | Type | Information Source | |
|---|---|---|---|
| GLUCOTROL Tablet | MPI, US: SPL/Old | FDA, National Drug Code (US) | |
| GLUCOTROL XL Extended-release tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| MINIDIAB Tablet | MPI, EU: SmPC | Pharmaceutical Benefits Scheme (AU) | |
| MINODIAB Tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.